Drugs / SAR110894
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01266525 | Feb 2011 → Jan 2013 | Alzheimer disease | Sanofi | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR110894 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01266525 ↗ |
| Action | Inhibit | “H3 receptor antagonist” NCT01266525 ↗ |
| Route | Oral | “Route of administration: Oral” NCT01266525 ↗ |